2026-01-24 - Analysis Report
**Company Overview**
AbbVie is a global biopharmaceutical company that develops and markets innovative solutions for various medical conditions.

**Return Rate Comparison**

* Cumulative Return of Review Stock (ABBV): **179.45%**
* Cumulative Return of Comparison Stock (S&P 500, VOO): **126.41%**
* Divergence: **53.00**
* Relative Divergence: **67.90%** (position at the top 67.9% percentile of past data)

**Stock Price Fluctuation Analysis**

* Latest Close: **$219.26**
* Last-Market Change: **$0.53** (0.24% increase)
* 5-day Moving Average: **$216.38**
* 20-day Moving Average: **$223.07**
* 60-day Moving Average: **$225.05**
* Latest Close is higher than the 5-day Moving Average indicating a sharp rebound.

**Indicators Analysis**

* RSI (Relative Strength Index): **40.08** (not overbought)
* PPO (Percent Price Oscillator): **-0.25** (indicating possible buying opportunity)
* Market Risk Indicator (MRI): **0.70** (medium investment risk)
* Hybrid Signal: Buy (Cash 0%)
* Recent (20 days) relative divergence change: **+5.30** (improving)
* 7-day Rank change: **+9** (rank up)
* 7-day Dynamic Expected Return change: **-14.00** (- worsening)
* Expected Return (%): **26.20%**

**Recent News & Significant Events**

* Positive Phase 3 Epcoritamab Lymphoma Results
* Increase in Shares Purchased by Strs Ohio
* Upcoming Quarterly Earnings Report expected to release soon
* Recent news indicates positive market sentiments for ABBV.

**Analyst Opinions**

- Analyst Consensus: Buy
- Mean: **1.93** (~ Buy)
- Opinions: **27**
- Target Price (avg/high/low): **245.22** / **289.00** / **184.00**

**Comprehensive Analysis (Summary of previous items)**

* The cumulative return of ABBV is significantly higher than the S&P 500 index.
* Recent trends show a sharp rebound, with a 0.24% increase in the latest close.
* Indicators suggest possible buying opportunity with a medium investment risk.
* Recent news and analysts' opinions indicate positive market sentiments for ABBV.
* With a mean rating of 1.93 and a target price of 245.22, ABBV appears to be an attractive investment opportunity for long-term investors.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.